drugset / Trial / NCT07539688
Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label, single-arm, prospective clinical trial involving patients with relapsed/refractory B-cell lymphoma, aimed at evaluating the safety and efficacy of CAR-T cell infusion.
Timeline
- Start
- 2026-05-01
- Primary completion
- 2029-03-01
- Completion
- 2029-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CY-219 | Unknown | 1e+06 cells/kg | — |
| Subject | CY-219 | Unknown | 2e+06 cells/kg | — |
| Subject | CY-219 | Unknown | 3e+06 cells/kg | — |